openPR Logo
Press release

IMARC Study Forecasts the Chinese diabetes market to exceed US$ 2.8 Billion by 2015

09-20-2010 08:00 AM CET | Advertising, Media Consulting, Marketing Research

Press release from: IMARC Group

As the second largest economy of the world, China enjoys pink of health but its affluence is giving rise to another sickness- a rapid increase in a life-style disease called diabetes. With the Chinese Population getting richer, fatter and less mobile, there has been a surge in the prevalence of diabetes. Further fuelled by rising disposable incomes, the diabetes market- Non-Insulin Anti-diabetics and Insulin, is expanding by more than 25% percent a year, and thus creating lucrative opportunities for global pharmaceutical companies at a time when rates in the more developed markets have declined.

China’s diabetes market grew at CAGR of 26% in the last five years with sales touching US$ 642 Million in 2009. In a country with around 10% of the total population being above 65 years of age, nearly 100 Million people obese and overweight, and with urbanization rates in an increasing mode, we expect the market to more than quadruple vis-à-vis its present level by 2015.

IMARC’s new report “China Diabetes Market Report & Outlook for 2010-2015” gives a deep insight into the Chinese diabetes market. The research study serves as an analytical as well as statistical tool to understand the epidemiology, trends, market structure and segmentation, competitive landscape, drivers, restraints and the outlook of the diabetes market in China. The report can serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are looking to foray into the Chinese diabetes market in some form or the other.

Report Highlights

· Driven by strong performance of both Insulin and Non-Insulin Anti-diabetics, The Chinese diabetes market is expected to exceed US$ 2.8 Billion by 2015.

· In 2009, the market for Non-Insulin Anti-diabetics was worth US$ 357 Million. Four of the top five players were foreign multinationals, with Bayer being the leader with a 28% market share.

· Alpha Glycosidase Inhibitors represented the biggest non Insulin Anti-diabetes class with a share of 35% in 2009.

· Although DPP-IV Inhibitors have been available in China only since march 2010. We expect this class to show a strong uptake in the next five years and reach revenues worth US$ 172 Million.

· China’s Insulin market witnessed a CAGR growth of 31% between 2005-2009 and was worth US$ 285 Million in 2009.

· The Chinese Insulin market is strongly oligopolistic with top three players (all of them being multinationals) accounting for 92% of the total sales in 2009. In fact, one player (Novo Nordisk) accounted 71% of the total sales.

Forecasts: The report provides forecasts on:

· Number of diabetes patients

· Diagnosis and treatment rates in China

· Diabetes market

· Non-Insulin Anti-diabetics market

. Alpha-Glycosidase Inhibitors

. Glinides

. Glitazones

. Sulphonylureas

. DPP-IV Inhibhitors

. Biguanides

. GLP-1 Agonists

. All other Non-Insulin Anti-diabetic classes

· Insulin market


Competitive Landscape: This section covers:

· 2005-2009 sales and market shares of top players in the diabetes market

· 2005-2009 sales and market shares of top players in the Non-Insulin Anti-diabetics market

· 2005-2009 sales and market shares of top players in various Non-Insulin Drug Classes

· 2005-2009 sales of top drugs comprising the portfolio of key players in various Non-Insulin Drug Classes

· 2005-2009 sales and market shares of top players in the Insulin market

· 2005-2009 sales of top drugs comprising the portfolio of Key players in the Insulin market.


Key Questions Answered in this report

· What is the total size of the diabetes population in China and what are its characteristics?

· What are the diagnosis and drug treatment rates for diabetes in China?

· What are the key factors driving the growth of diabetes medication in China?

· What is the Size and Breakup of the total diabetes market in China?

· What is the Size and Breakup of the total Non-Insulin Anti-diabetics market in China?

· What is the Size and Breakup of the total Insulin market in China?

· Who are the key players in the Chinese diabetes market and how have they performed?

· What is the outlook of the Chinese diabetes market in the next five years?

· Which new products are expected to be launched in the next five years?

· Which therapy classes will show the highest growth in the next five years?

· What are the road blocks in the Chinese diabetes market?

To get the full version of "China diabetes market report and outlook for 2010-2015" please get in touch with us by emailing us at sales@imarcgroup.com or you can call us on +91-11-43095788

About IMARC

For more than 5 years, the International Market Analysis Research and Consulting Group has been a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

IMARC Group
Eastend Apartment Mayur Vihar Phase-1 Extention Delhi-110096, India
press@imarcgroup.com
+91-11-43095788

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release IMARC Study Forecasts the Chinese diabetes market to exceed US$ 2.8 Billion by 2015 here

News-ID: 145085 • Views:

More Releases from IMARC Group

Dimethyl Ether Market Valuation to Reach USD 15.73 Billion by 2033 - Industry Expanding at a CAGR of 8.09%
Dimethyl Ether Market Valuation to Reach USD 15.73 Billion by 2033 - Industry Ex …
Market Overview: The dimethyl ether market is experiencing significant growth momentum, driven by increasing demand for cleaner fuel alternatives, expanding applications in various industries, and supportive government policies promoting sustainable energy solutions. According to IMARC Group's latest research publication, "Dimethyl Ether Market Size, Share, Trends and Forecast by Raw Material, Application, End-Use Industry, and Region, 2025-2033", the global dimethyl ether market size reached USD 7.22 Billion in 2024. Looking forward, IMARC
Glucometer Manufacturing Plant Report 2025: Unit Setup, Cost and Requirements, Project Economics
Glucometer Manufacturing Plant Report 2025: Unit Setup, Cost and Requirements, P …
Setting up a glucometer manufacturing plant requires thorough market research alongside a minute understanding of numerous operating factors such as unit processes, purchasing of raw materials, utility supply, infrastructure creation, equipment and technology specifications, human resource planning, logistics, and cash outlay. IMARC Group's report titled "Glucometer Manufacturing Plant Cost Analysis Report 2025: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue" offers a comprehensive guide for establishing a
Acetyltributyl Citrate Production Plant Cost Analysis Report 2025: Project Details and Machinery Requirements
Acetyltributyl Citrate Production Plant Cost Analysis Report 2025: Project Detai …
Establishing an acetyltributyl citrate plant will require a thorough market research, as well as a hard-granular understanding of various processes in the business such as unit operations, provision of raw materials, utilities, facility setup, equipment and technologies, human resources, logistics, and economics. IMARC Group's report titled "Acetyltributyl Citrate Production Plant Cost Analysis Report 2025: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue" offers a comprehensive guide for
eSIM Market Size, Share, Growth And Trends Report 2025-2033
eSIM Market Size, Share, Growth And Trends Report 2025-2033
eSIM Market Overview: The eSIM (embedded SIM) market is expanding rapidly as digital connectivity and IoT adoption reshape global communication technologies. Unlike traditional SIM cards, eSIMs are embedded directly into devices, enabling remote provisioning and seamless switching between network operators. This technology is gaining traction across smartphones, wearables, tablets, connected cars, industrial IoT, and smart home devices. The growing need for flexible, secure, and cost-efficient connectivity is driving market growth, along

All 5 Releases


More Releases for Insulin

Advancing Insulin Delivery Systems boost the Global Insulin Path Pumps Market
Inkwood Research expects the Global Insulin Patch Pumps Market to surge with a 10.63% CAGR by 2032, and is set to generate $2760.98 million during the forecast period 2023-2032. Browse 50 market data Tables and 47 Figures spread over 173 Pages, along with an in-depth analysis of the Global Insulin Patch Pumps Market by Type, Delivery Mode, Disease Indication, Distribution Channel, & by Geography. Refer to the Report Summary Here: https://inkwoodresearch.com/reports/insulin-patch-pumps-market/#report-summary This insightful
Advancing Insulin Delivery Systems boost the Global Insulin Path Pumps Market
Inkwood Research expects the Global Insulin Patch Pumps Market to surge with a 10.63% CAGR by 2032, and is set to generate $2760.98 million during the forecast period 2023-2032. Browse 50 market data Tables and 47 Figures spread over 173 Pages, along with an in-depth analysis of the Global Insulin Patch Pumps Market by Type, Delivery Mode, Disease Indication, Distribution Channel, & by Geography. Refer to the Report Summary Here: https://inkwoodresearch.com/reports/insulin-patch-pumps-market/#report-summary This insightful
Advancing Insulin Delivery Systems boost the Global Insulin Path Pumps Market
Inkwood Research expects the Global Insulin Patch Pumps Market to surge with a 10.63% CAGR by 2032, and is set to generate $2760.98 million during the forecast period 2023-2032. Browse 50 market data Tables and 47 Figures spread over 173 Pages, along with an in-depth analysis of the Global Insulin Patch Pumps Market by Type, Delivery Mode, Disease Indication, Distribution Channel, & by Geography. Refer to the Report Summary Here: https://inkwoodresearch.com/reports/insulin-patch-pumps-market/#report-summary This insightful
Insulin Pumps Market Share, Trends and Growth Analysis By Type (Traditional Insu …
Insulin Pumps Market is expected to register a CAGR of 15.5% and acquire the market value of USD 11.5 Billion by 2028 during forecast period 2023-2032. Insulin pumps are discreet, electronic medical devices that can be tucked beneath clothing or fastened to a belt. In order to regulate the rise in blood glucose levels, the pump is used to deliver controlled quantities of insulin within the body at regular intervals
Insulin Patch Pumps Market Report 2018: Segmentation by Insulin Type (Bolus Insu …
Global Insulin Patch Pumps market research report provides company profile for Roche Holding AG, Cellnovo Group SA, Spring Health Solution Ltd., Debiotech, CeQur SA, Valeritas, Becton Dickenson & Company, Insulet Corporation, Johnson & Johnson, Medtrum Technologies Inc. and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue,
Insulin pump Market Explore Future Growth 2018-2026 by Global Type-Traditional i …
Insulin pump is a portable device attached to the body that continuously delivers preset amounts of short or rapid acting insulin in the body to control diabetes. Insulin therapy is required in type 1 diabetes and sometime in type 2 diabetes. It serves as an effective alternative to insulin injections. Furthermore, insulin pump delivers the insulin according to the need of body as basal rate, where small amount of insulin